• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.（+）-4-丙基-9-羟基萘恶嗪作为帕金森病辅助治疗的疗效。
J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):732-5. doi: 10.1136/jnnp.52.6.732.
2
The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.经皮给药（+）-4-丙基-9-羟基萘并恶嗪（+PHNO）的抗帕金森病作用及药代动力学：初步结果
Mov Disord. 1989;4(2):129-38. doi: 10.1002/mds.870040204.
3
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.MK 458，一种用于晚期帕金森病的选择性强效D2受体激动剂。
Clin Neuropharmacol. 1988 Jun;11(3):191-200. doi: 10.1097/00002826-198806000-00001.
4
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.帕金森病控释型MK-458（PHNO）单药治疗：双盲研究及与卡比多巴/左旋多巴的比较
Clin Neuropharmacol. 1991 Jun;14(3):214-27. doi: 10.1097/00002826-199106000-00004.
5
Differential progression of motor impairment in levodopa-treated Parkinson's disease.左旋多巴治疗帕金森病中运动障碍的差异进展
Mov Disord. 2000 May;15(3):479-84. doi: 10.1002/1531-8257(200005)15:3<479::AID-MDS1009>3.0.CO;2-P.
6
(+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.（+）-4-丙基-9-羟基萘并恶嗪在帕金森病中的应用
Lancet. 1986 Apr 19;1(8486):906. doi: 10.1016/s0140-6736(86)91004-4.
7
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.缓释（+）-PHNO [MK-458（羟丙基甲基纤维素）]治疗帕金森病：对作为长效制剂给予的选择性D2受体激动剂产生耐受性的证据。
Mov Disord. 1990;5(4):298-303. doi: 10.1002/mds.870050407.
8
Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.帕金森病中经鼻胃管和静脉输注（+）-4-丙基-9-羟基萘恶嗪（PHNO）
J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):102-5. doi: 10.1136/jnnp.53.2.102.
9
[Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].[肠道左旋多巴/卡比多巴凝胶治疗晚期帕金森病：疗效与安全性综述]
Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(11):145-51.
10
[Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].[从传统左旋多巴直接转换为息宁（左旋多巴/卡比多巴/恩他卡朋）可改善帕金森病患者的生活质量：一项开放标签临床研究的结果]
Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(1):51-4.

引用本文的文献

1
Nano-FeO@walnut shell/Cu(ii) as a highly effective environmentally friendly catalyst for the one-pot three-component synthesis of 1,3-oxazine derivatives under solvent-free conditions.纳米FeO@核桃壳/Cu(ii)作为一种高效环保型催化剂，用于在无溶剂条件下一锅法三组分合成1,3-恶嗪衍生物。
RSC Adv. 2020 Aug 28;10(53):31874-31880. doi: 10.1039/d0ra04282j. eCollection 2020 Aug 26.
2
EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality.欧洲核医学协会放射性药物摩尔活度或比活度协调指南：对安全性和成像质量的影响
EJNMMI Radiopharm Chem. 2021 Oct 9;6(1):34. doi: 10.1186/s41181-021-00149-6.

本文引用的文献

1
Recognizing neurotoxic disease.识别神经毒性疾病。
Neurology. 1987 Feb;37(2):276-8. doi: 10.1212/wnl.37.2.276.
2
PHNO, a novel dopamine agonist, in animal models of parkinsonism.PHNO，一种新型多巴胺激动剂，在帕金森病动物模型中的研究。
Mov Disord. 1987;2(3):193-9. doi: 10.1002/mds.870020306.
3
Antiparkinsonian activity of a single oral dose of PHNO.单次口服PHNO的抗帕金森病活性。
Mov Disord. 1987;2(1):47-51. doi: 10.1002/mds.870020106.
4
PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agent.PHNO [（+）-4-丙基-9-羟基萘并恶嗪]：一种新型有效的抗帕金森病药物。
Neurology. 1988 Oct;38(10):1541-5. doi: 10.1212/wnl.38.10.1541.
5
(+)-4-Propyl-9-hydroxynaphthoxazine (PHNO), a new dopaminomimetic, in treatment of parkinsonism.新型拟多巴胺药物（+）-4-丙基-9-羟基萘并恶嗪（PHNO）治疗帕金森病。
Lancet. 1985 Dec 14;2(8468):1330-1. doi: 10.1016/s0140-6736(85)92627-3.

（+）-4-丙基-9-羟基萘恶嗪作为帕金森病辅助治疗的疗效。

The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.

作者信息

Weiner W J, Factor S A, Sanchez-Ramos J R

机构信息

Department of Neurology, University of Miami School of Medicine, Florida 33136.

出版信息

J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):732-5. doi: 10.1136/jnnp.52.6.732.

DOI:10.1136/jnnp.52.6.732
PMID:2746265
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1032023/
Abstract

(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) is a novel selective D2 agonist. The efficacy and safety of PHNO was studied in 10 Parkinsonian patients (Hoehn and Yahr Stage II or III) who continued to receive levodopa/carbidopa. At the lowest dose administered (0.25 mg tid), nine of the 10 patients improved with respect to rigidity, bradykinesia and tremor. At this dose there was one dropout because of severe orthostasis. Although there was a trend towards improvement in motor scores with the higher doses (0.5-1.0 mg tid), this was not statistically significant. At higher doses there were a total of four dropouts because of adverse effects such as nausea, vomiting and orthostatic hypotension. It appears that PHNO may prove to be efficacious in the treatment of Parkinson's disease.

摘要

（+）-4-丙基-9-羟基萘并恶嗪（PHNO）是一种新型的选择性D2激动剂。在10名继续接受左旋多巴/卡比多巴治疗的帕金森病患者（Hoehn和Yahr分期为II期或III期）中研究了PHNO的疗效和安全性。在给予的最低剂量（0.25毫克，每日三次）时，10名患者中有9名在强直、运动迟缓及震颤方面有所改善。在此剂量下，有1名患者因严重直立性低血压退出研究。尽管较高剂量（0.5 - 1.0毫克，每日三次）时有运动评分改善的趋势，但这在统计学上并不显著。在较高剂量时，共有4名患者因恶心、呕吐及直立性低血压等不良反应而退出研究。看来PHNO可能被证明对帕金森病的治疗有效。